secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001698530-26-000007
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics
--------------------------------------------------------------------------------

- Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.
- Milestone payment of $1,000,000 due to GPCR Therapeutics Inc. within 30 days.
- Achievement triggers improved future sublicensing income-sharing ratio for Exicure.
- Milestone reflects progress in development of small-molecule CXCR4 inhibitor Burixafor (GPC-100).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853026000007/0001698530-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853026000007/xcur-20260116.htm
  HTML page:      https://secwatch.observer/filing/0001698530-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer